Global Biopharmaceuticals Market Report and Forecast 2023-2031
Global Biopharmaceuticals Market Outlook:
The global biopharmaceuticals market value was USD 407.8 billion in 2022, driven by the increasing prevalence of chronic diseases, advancements in biotechnology across the globe. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2023-2031 to achieve a value of USD 788.4 billion by 2031.
Introduction
Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from living organisms or produced through biotechnology processes. They are widely used in the treatment and prevention of various diseases, including cancer, autoimmune disorders, and genetic disorders. Biopharmaceuticals offer targeted therapies with high efficacy and fewer side effects compared to traditional chemical-based drugs.
Key Trends in the Biopharmaceuticals Market
Some key trends involved in the Biopharmaceuticals market are as follows:
The market for biopharmaceuticals has been experiencing significant growth in recent years. This can be attributed to several key trends shaping the industry:
Advancements in Biotechnology: Rapid advancements in biotechnology have revolutionized the development and manufacturing processes of biopharmaceuticals. This includes the use of recombinant DNA technology, genetic engineering, and cell culture techniques to produce complex proteins, antibodies, and other biologically active molecules.
Increasing Focus on Personalized Medicine: Biopharmaceuticals play a crucial role in personalized medicine, where treatments are tailored to the individual patient based on their genetic profile, biomarkers, and disease characteristics. This trend is driven by advancements in genomic sequencing, biomarker identification, and companion diagnostics, allowing for more targeted and effective therapies.
Biopharmaceuticals Market Segmentations
Market Breakup by Product Type
Monoclonal Antibodies
Anti-Cancer Monoclonal Antibodies
Anti-Inflammatory Monoclonal Antibodies
Others
Recombinant Growth Factors
Erythropoietin
Granulocyte Colony Stimulating Factor
Purified Proteins
Leukemia Inhibitory Factor (LIF)
P53 Protein
P38 Protein
Others
Recombinant Proteins
Serum Albumin
Amyloid Protein
Defensin
Transferrin
Recombinant Hormones
Recombinant Human Growth Hormones
Recombinant Insulin
Others
Vaccines
Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccine
Hepatitis B Vaccine
Tetanus Vaccine
Diphtheria Vaccine
Cholera Vaccines
Others
Conventional Vaccines
Polio Vaccine
Pox Vaccine
Others
Recombinant Enzyme
Enterokinase
Cyclase
Caspase
Cathepsin
Cell and Gene Therapies
Allogenic Products
Autologous Products
Acellular Products
Synthetic Immunomodulators
Cytokines, Interferons, and Interleukins
Others
Market Breakup by Therapeutic Application
Oncology
Inflammatory and Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
Cardiovascular Diseases
Neurological Diseases
Others
Market Breakup by Region
North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others
Biopharmaceuticals Market Scenario
The biopharmaceuticals market is a rapidly growing and dynamic sector within the pharmaceutical industry. Biopharmaceuticals, also known as biologics, are a class of drugs that are derived from living organisms or produced through biotechnology processes. They have revolutionized the treatment and prevention of various diseases, offering targeted therapies with high efficacy and fewer side effects compared to traditional chemical-based drugs.
The market for biopharmaceuticals has experienced significant growth in recent years, driven by factors such as increasing prevalence of chronic diseases, advancements in biotechnology, and growing demand for personalized medicine. Biopharmaceuticals have demonstrated remarkable success in treating conditions such as cancer, autoimmune disorders, diabetes, and rare genetic diseases.
Overall, the biopharmaceuticals market presents significant opportunities for growth and innovation. With ongoing research and development efforts, increasing investment in biotechnology, and evolving regulatory frameworks, the market is expected to continue its upward trajectory in the coming years. The focus on personalized medicine, biosimilars, and expanding access to biopharmaceuticals globally will be key drivers of market growth.
Biopharmaceuticals Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Amgen Inc.
AbbVie Inc.
Bristol-Myers Squibb Company.
Eli Lilly and Company
Novo Nordisk A/S
Pfizer Inc.
GlaxoSmithKline plc.
Abbott
Astrazeneca
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bayer AG
Biogen
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Biopharmaceuticals Market Overview
- 3.1 Global Biopharmaceuticals Market Historical Value (2016-2022)
- 3.2 Global Biopharmaceuticals Market Forecast Value (2023-2031)
- 4 Global Biopharmaceuticals Market Landscape
- 4.1 Global Biopharmaceuticals Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Biopharmaceuticals Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Therapeutic Application
- 5 Global Biopharmaceuticals Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Biopharmaceuticals Market Segmentation
- 6.1 Global Biopharmaceuticals Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Monoclonal Antibodies
- 6.1.2.1 Anti-Cancer Monoclonal Antibodies
- 6.1.2.2 Anti-Inflammatory Monoclonal Antibodies
- 6.1.2.3 Others
- 6.1.3 Recombinant Growth Factors
- 6.1.3.1 Erythropoietin
- 6.1.3.2 Granulocyte Colony Stimulating Factor
- 6.1.4 Purified Proteins
- 6.1.4.1 Leukemia Inhibitory Factor (LIF)
- 6.1.4.2 P53 Protein
- 6.1.4.3 P38 Protein
- 6.1.4.4 Others
- 6.1.5 Recombinant Proteins
- 6.1.5.1 Serum Albumin
- 6.1.5.2 Amyloid Protein
- 6.1.5.3 Defensin
- 6.1.5.4 Transferrin
- 6.1.6 Recombinant Hormones
- 6.1.6.1 Recombinant Human Growth Hormones
- 6.1.6.2 Recombinant Insulin
- 6.1.6.3 Others
- 6.1.7 Vaccines
- 6.1.7.1 Recombinant Vaccines
- 6.1.7.1.1 Cancer Vaccines
- 6.1.7.1.2 Malaria Vaccines
- 6.1.7.1.3 Ebola Vaccine
- 6.1.7.1.4 Hepatitis B Vaccine
- 6.1.7.1.5 Tetanus Vaccine
- 6.1.7.1.6 Diphtheria Vaccine
- 6.1.7.1.7 Cholera Vaccines
- 6.1.7.1.8 Others
- 6.1.7.2 Conventional Vaccines
- 6.1.7.2.1 Polio Vaccine
- 6.1.7.2.2 Pox Vaccine
- 6.1.7.2.3 Others
- 6.1.8 Recombinant Enzyme
- 6.1.8.1 Enterokinase
- 6.1.8.2 Cyclase
- 6.1.8.3 Caspase
- 6.1.8.4 Cathepsin
- 6.1.9 Cell and Gene Therapies
- 6.1.9.1 Allogenic Products
- 6.1.9.2 Autologous Products
- 6.1.9.3 Acellular Products
- 6.1.10 Synthetic Immunomodulators
- 6.1.10.1 Cytokines, Interferons, and Interleukins
- 6.1.11 Others
- 6.2 Global Biopharmaceuticals Market by Therapeutic Application
- 6.2.1 Market Overview
- 6.2.2 Oncology
- 6.2.3 Inflammatory and Infectious Diseases
- 6.2.4 Autoimmune Disorders
- 6.2.5 Metabolic Disorders
- 6.2.6 Hormonal Disorders
- 6.2.7 Cardiovascular Diseases
- 6.2.8 Neurological Diseases
- 6.2.9 Others
- 6.3 Global Biopharmaceuticals Market by Region
- 6.3.1 Market Overview
- 6.3.2 North America
- 6.3.3 Europe
- 6.3.4 Asia Pacific
- 6.3.5 Latin America
- 6.3.6 Middle East and Africa
- 7 North America Biopharmaceuticals Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Biopharmaceuticals Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Biopharmaceuticals Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Biopharmaceuticals Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Biopharmaceuticals Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
- 17.1 Amgen Inc.
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 AbbVie Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Bristol-Myers Squibb Company.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Eli Lilly and Company
- 17.4.1 Financial Analysis
- 17.4.2 Financial Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Novo Nordisk A/S
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Pfizer Inc.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 GlaxoSmithKline plc.
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Abbott
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Astrazeneca
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 F. Hoffmann-La Roche Ltd.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Merck & Co., Inc.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Bayer AG
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Biogen
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 18 Global Biopharmaceuticals Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook